{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-011554","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.695951+00:00","generated_at":"2026-06-25T02:18:08.553540+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Fate Therapeutics shareholders approve 2022 Stock Plan, elect all director nominees","bullets":["Stockholders approved 2022 Stock Option and Incentive Plan with 61.5M for, 23.2M against, 84.7K abstain.","Class III directors Coughlin, Wolchko, and Agarwal elected; Agarwal received 69.7M for, 15.0M withheld.","Ratification of Ernst & Young as auditor for FY2022 passed with 90.1M for, 69K against.","Non-binding advisory vote on executive compensation passed with 75.4M for, 9.1M against.","Broker non-votes of 5.5M shares on director election, say-on-pay, and plan approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-011554","json":"https://secwatch.observer/filing/0000950170-22-011554.json","markdown":"https://secwatch.observer/filing/0000950170-22-011554.md","text":"https://secwatch.observer/filing/0000950170-22-011554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/0000950170-22-011554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022011554/fate-20220609.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:18:08.553540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}